Skip to Content
 

VICC toll-free number 1-877-936-8422

Douglas  Johnson

Douglas Johnson, M.D., M.S.C.I.

Assistant Professor of Medicine
Clinical Director, Melanoma
Medical Oncologist

  • Appointments
    615-935-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    (615) 322-4967

    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-3524
  • Faxes
    Division of Hematology/Oncology Fax
    (615) 343-7602
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Clinic
    1301 Medical Center Drive
    1710 The Vanderbilt Clinic
    Nashville, TN 37232

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    777 Preston Research Building
    2220 Pierce Avenue
    Nashville, TN 37232
Profile

Dr. Johnson is a medical oncologist specializing in melanoma skin cancer. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.

 

Dr. Johnson leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. Specifically, he is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. Dr. Johnson is the lead investigator on numerous clinical trials at Vanderbilt.

Education
  • M.D., University of Alabama at Birmingham
  • Residency, Duke University
  • Fellowship, Vanderbilt University
  • M.S.C.I., Vanderbilt University
 
Publications
  • Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J. Immunother [print-electronic]. 2016 Nov 11/14/2016; PMID: 27846054, DOI: 10.1097/CJI.0000000000000148, ISSN: 1537-4513.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27846054.
  • Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N. Engl. J. Med. 2016 Nov 11/3/2016; 375(18): 1749-55. PMID: 27806233, DOI: 10.1056/NEJMoa1609214, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27806233.
  • Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol [print-electronic]. 2016 Sep 9/29/2016; PMID: 27687304, PII: mdw443, DOI: 10.1093/annonc/mdw443, ISSN: 1569-8041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27687304.
  • Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller V, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res [print-electronic]. 2016 Sep 9/26/2016; PMID: 27671167, PII: 2326-6066.CIR-16-0143, DOI: 10.1158/2326-6066.CIR-16-0143, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27671167.
  • Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer [print-electronic]. 2016 Aug 8/17/2016; PMID: 27533448, DOI: 10.1002/cncr.30258, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27533448.
  • Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer [print-electronic]. 2016 Aug 8/17/2016; PMID: 27533633, DOI: 10.1002/cncr.30259, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27533633.
  • Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 Aug; 14(8): 945-58. PMID: 27496110, PII: 14/8/945, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27496110.
  • Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J. Leukoc. Biol [print-electronic]. 2016 Aug; 100(2): 275-90. PMID: 27256570, PII: jlb.5RI0116-013RR, DOI: 10.1189/jlb.5RI0116-013RR, ISSN: 1938-3673.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27256570.
  • Beckermann KE, Johnson DB, Sosman JA. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol [print-electronic]. 2016 Jul 7/28/2016; 1-8. PMID: 27426025, DOI: 10.1080/1744666X.2016.1214575, ISSN: 1744-8409.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27426025.
  • Greenplate AR, Johnson DB, Ferrell PB, Irish JM. Systems immune monitoring in cancer therapy. Eur. J. Cancer [print-electronic]. 2016 Jul; 61: 77-84. PMID: 27155446, PMCID: PMC4885747, PII: S0959-8049(16)32047-0, DOI: 10.1016/j.ejca.2016.03.085, ISSN: 1879-0852.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27155446.
  • Shreders A, Joseph R, Peng C, Ye F, Zhao S, Puzanov I, Sosman JA, Johnson DB. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunol Res [print-electronic]. 2016 Jul; 4(7): 569-73. PMID: 27197063, PMCID: PMC4940026, PII: 2326-6066.CIR-15-0281, DOI: 10.1158/2326-6066.CIR-15-0281, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27197063.
  • Johnson DB, Pollack MH, Sosman JA. Emerging targeted therapies for melanoma. Expert Opin Emerg Drugs [print-electronic]. 2016 Jun; 21(2): 195-207. PMID: 27148822, DOI: 10.1080/14728214.2016.1184644, ISSN: 1744-7623.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27148822.
  • Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Melanoma driver mutations and immune therapy. Oncoimmunology. 2016 May; 5(5): e1051299. PMID: 27467925, PMCID: PMC4910708, PII: 1051299, DOI: 10.1080/2162402X.2015.1051299, ISSN: 2162-4011.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27467925.
  • Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko J, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res [print-electronic]. 2016 Apr 4/18/2016; PMID: 27089234, DOI: 10.1111/pcmr.12482, ISSN: 1755-148X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27089234.
  • Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. SFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature [print-electronic]. 2016 Apr 4/4/2016; PMID: 27042933, PII: nature17392, DOI: 10.1038/nature17392, ISSN: 1476-4687.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27042933.
  • Rioth MJ, Thota R, Staggs DB, Johnson DB, Warner JL. Pragmatic Precision Oncology: The Secondary Uses of Clinical Tumor Molecular Profiling. J Am Med Inform Assoc [print-electronic]. 2016 Mar 3/28/2016; PMID: 27026612, PII: ocw002, DOI: 10.1093/jamia/ocw002, ISSN: 1527-974X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27026612.
  • Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell [print-electronic]. 2016 Mar 3/24/2016; 165(1): 35-44. PMID: 26997480, PMCID: PMC4808437, PII: S0092-8674(16)30215-X, DOI: 10.1016/j.cell.2016.02.065, ISSN: 1097-4172.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26997480.
  • Greenplate AR, Johnson DB, Roussel M, Savona MR, Sosman JA, Puzanov I, Ferrell PB, Irish JM. Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. Cancer Immunol Res [print-electronic]. 2016 Mar 3/10/2016; PMID: 26966176, PII: 2326-6066.CIR-15-0213, DOI: 10.1158/2326-6066.CIR-15-0213, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26966176.
  • Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb 2/1/2016; 2(2): 234-40. PMID: 26633184, PII: 2473508, DOI: 10.1001/jamaoncol.2015.4368, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26633184.
  • Johnpulle RA, Johnson DB, Sosman JA. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep. 2016 Jan; 18(1): 6. PMID: 26743513, PII: 10.1007/s11912-015-0485-6, DOI: 10.1007/s11912-015-0485-6, ISSN: 1534-6269.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26743513.
  • Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26176864.
  • Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016; 7: 10582. PMID: 26822383, PMCID: PMC4740184, PII: ncomms10582, DOI: 10.1038/ncomms10582, ISSN: 2041-1723.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26822383.
  • Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016; 4: 60. PMID: 27777770, PMCID: PMC5067899, PII: 166, DOI: 10.1186/s40425-016-0166-5.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27777770.
  • Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer [print-electronic]. 2015 Dec; 51(18): 2792-9. PMID: 26608120, PMCID: PMC4666799, PII: S0959-8049(15)00821-7, DOI: 10.1016/j.ejca.2015.08.022, ISSN: 1879-0852.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26608120.
  • Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. J. Clin. Oncol [print-electronic]. 2015 Nov 11/20/2015; 33(33): e122-4. PMID: 24778401, PII: JCO.2013.51.1683, DOI: 10.1200/JCO.2013.51.1683, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24778401.
  • Johnson DB, Mudigonda TV, Sosman JA. Melanoma and a Headache. Diagnosis: Hypophysitis. JAMA Oncol. 2015 Nov; 1(8): 1167-8. PMID: 26225893, PII: 2398983, DOI: 10.1001/jamaoncol.2015.2537, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26225893.
  • Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26359985.
  • Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015 Sep 9/8/2015; 6(26): 22348-60. PMID: 26084293, PMCID: PMC4673168, PII: 4255, DOI: 10.18632/oncotarget.4255, ISSN: 1949-2553.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26084293.
  • Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, Johnson DB, Lumbang WA, Moody BR, Prescott JL, Chandra PK, Boyd AS, Zwerner JP, Robbins JB, Tyring SK, Rady PL, Chappell JD, Shyr Y, Infante JR, Sosman JA. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin. Cancer Res [print-electronic]. 2015 Jun 6/1/2015; 21(11): 2624-34. PMID: 25724524, PMCID: PMC4452444, PII: 1078-0432.CCR-14-2667, DOI: 10.1158/1078-0432.CCR-14-2667, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25724524.
  • Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist [print-electronic]. 2015 Jun; 20(6): 648-52. PMID: 25964307, PMCID: PMC4571784, PII: theoncologist.2014-0468, DOI: 10.1634/theoncologist.2014-0468, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25964307.
  • Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol. 2015 Jun; 1(3): 380-6. PMID: 26181188, PII: 2276102, DOI: 10.1001/jamaoncol.2015.0565, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26181188.
  • Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25649350.
  • Thota R, Johnson DB, Sosman JA. Trametinib in the treatment of melanoma. Expert Opin Biol Ther [print-electronic]. 2015 May; 15(5): 735-47. PMID: 25812921, DOI: 10.1517/14712598.2015.1026323, ISSN: 1744-7682.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25812921.
  • Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol. 2015 Apr; 16(4): 15. PMID: 25796376, DOI: 10.1007/s11864-015-0330-z, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25796376.
  • Ohri N, Duan F, Machtay M, Gorelick JJ, Snyder BS, Alavi A, Siegel BA, Johnson DW, Bradley JD, DeNittis A, Werner-Wasik M. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J. Natl. Cancer Inst [electronic-print]. 2015 Apr; 107(4): PMID: 25688115, PMCID: PMC4402361, PII: djv004, DOI: 10.1093/jnci/djv004, ISSN: 1460-2105.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25688115.
  • Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25736262.
  • Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2): 97-106. PMID: 25755682, PMCID: PMC4346215, PII: 10.1177_1758834014567469, DOI: 10.1177/1758834014567469, ISSN: 1758-8340.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755682.
  • Jiang W, Jia P, Hutchinson KE, Johnson DB, Sosman JA, Zhao Z. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget. 2015 Feb 2/10/2015; 6(4): 2496-508. PMID: 25537510, PMCID: PMC4385866, PII: 2954, DOI: 10.18632/oncotarget.2954, ISSN: 1949-2553.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25537510.
  • Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25600339.
  • Jackson LK, Johnson DB, Sosman JA, Murphy BA, Epstein JB. Oral health in oncology: impact of immunotherapy. Support Care Cancer [print-electronic]. 2015 Jan; 23(1): 1-3. PMID: 25216852, DOI: 10.1007/s00520-014-2434-6, ISSN: 1433-7339.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25216852.
  • Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy [print-electronic]. 2015; 7(6): 611-9. PMID: 26098919, PMCID: PMC4519012, DOI: 10.2217/imt.15.35, ISSN: 1750-7448.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26098919.
  • Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4): 658-69. PMID: 25096781, PMCID: PMC4216599, DOI: 10.1007/s11864-014-0305-5, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25096781.
  • Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol [print-electronic]. 2014 Nov 11/20/2014; 32(33): 3697-704. PMID: 25287827, PMCID: PMC4226803, PII: JCO.2014.57.3535, DOI: 10.1200/JCO.2014.57.3535, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25287827.
  • Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin. Cancer Res [print-electronic]. 2014 Aug 8/15/2014; 20(16): 4186-92. PMID: 24895460, PMCID: PMC4134689, PII: 1078-0432.CCR-13-3270, DOI: 10.1158/1078-0432.CCR-13-3270, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24895460.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24599935.
  • Johnson DB, Sosman JA. BRAFV600E-mutant melanoma presenting with cardiac involvement. J Natl Compr Canc Netw. 2014 May; 12(5): 611-5. PMID: 24812130, PMCID: PMC4182311, PII: 12/5/611, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24812130.
  • Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, PII: 2159-8290.CD-13-0642, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24265155.
  • Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. Case Rep Oncol Med [print-electronic]. 2014; 2014: 341980. PMID: 25328733, PMCID: PMC4190830, DOI: 10.1155/2014/341980, ISSN: 2090-6706.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25328733.
  • Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013 Dec; 1(6): 373-7. PMID: 24490176, PMCID: PMC3905602, DOI: 10.1158/2326-6066.CIR-13-0092, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24490176.
  • Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013 Jun; 14(2): 280-92. PMID: 23420410, DOI: 10.1007/s11864-013-0226-8, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23420410.
  • Johnson DB, Savani BN. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?. Exp. Hematol [print-electronic]. 2012 Jul; 40(7): 513-7. PMID: 22542577, PII: S0301-472X(12)00138-5, DOI: 10.1016/j.exphem.2012.04.004, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22542577.